Treatment outcomes and prognosis of immune checkpoint inhibitors therapy in patients with advanced thymic carcinoma: A multicentre retrospective study
文献类型：期刊论文
| 作者 | Wang, Wenxian1,3; Lin, Gen4; Guan, Yelan1; Zhang, Yuxin2; Xu, Chunwei5; Wang, Qian6; Wang, Dong5; Jiang, Zhansheng7; Cai, Jing8; Lou, Guangyuan1,3 |
| 刊名 | EUROPEAN JOURNAL OF CANCER
 |
| 出版日期 | 2022-10-01 |
| 卷号 | 174 |
| 关键词 | Thymic carcinoma Immunotherapy PD-1 Efficacy Immune-related adverse events |
| ISSN号 | 0959-8049 |
| DOI | 10.1016/j.ejca.2022.06.059 |
| 通讯作者 | Song, Zhengbo(zheng_bo_song@163.com) ; Zhang, Yongchang(zhangyongchang@csu.edu.cn) |
| 英文摘要 | Background: Immunotherapy has demonstrated good efficacy and survival out-comes in solid tumours. However, efficacy data for immune checkpoint inhibitors (ICIs) in advanced thymic carcinoma are lacking. The present study aimed to assess the activity of ICIs in advanced thymic carcinoma.Methods: A multicentre retrospective study was conducted to explore the efficacy and safety of ICIs for advanced thymic carcinoma. Objective response rate (ORR), progression-free sur-vival (PFS), overall survival, and immune-related adverse events (irAEs) were analysed. In addition, factors independently associated with treatment efficacy and survival outcomes were evaluated.Results: A total of 77 patients with advanced thymic carcinoma were enrolled between March 2016 and September 2021. The ORR was existing the difference between ICIs monotherapy (n = 23) and ICIs combined with chemotherapy (n = 54) (17.4% versus 44.4%, P = 0.024). The ICIs combination treatments were associated with better median PFS (mPFS) compared to ICIs monotherapy (12.7 months versus 2.1 months, P < 0.001). Notably, liver or brain metastasis was a poor prognostic factor of mPFS (1.8 months versus 3.5 months, P = 0.012) in the ICIs monotherapy group. In addition, mPFS for the first-line treatment (n = 27) was longer than that for ICIs as the second-or posterior-line treatment (n = 50) (P < 0.001). The incidence of irAEs was 54.5% (42/77) in the 77 enrolled patients. The inci-dence of grade 3-4 irAE was 15.6% (12/77).Conclusions: Immunotherapy is effective in advanced thymic carcinoma, especially for combi-nation with chemotherapy showed promising antitumour activity, which indicates worthy of combination treatment strategy for further study. IrAEs also require close monitoring and management. 2022 Elsevier Ltd. All rights reserved. |
| WOS关键词 | PHASE-II ; SINGLE-CENTER ; CARBOPLATIN ; THYMOMA ; PACLITAXEL ; CHEMOTHERAPY ; NIVOLUMAB ; ARM |
| WOS研究方向 | Oncology |
| 语种 | 英语 |
| WOS记录号 | WOS:000880826800003 |
| 出版者 | ELSEVIER SCI LTD |
| 源URL | [http://ir.hfcas.ac.cn:8080/handle/334002/130150]  |
| 专题 | 中国科学院合肥物质科学研究院 |
| 通讯作者 | Song, Zhengbo; Zhang, Yongchang |
| 作者单位 | 1.Univ Chinese Acad Sci, Canc Hosp, Zhejiang Canc Hosp, Dept Med Oncol, Hangzhou, Peoples R China 2.Hangzhou Canc Hosp, Dept Radiotherapy, Hangzhou, Peoples R China 3.Chinese Acad Sci, Inst Basic Med & Canc IBMC, Hangzhou, Peoples R China 4.Fujian Med Univ, Fujian Canc Hosp, Canc Hosp, Dept Thorac Oncol, Fuzhou, Peoples R China 5.Nanjing Univ, Jinling Hosp, Sch Med, Dept Resp Med, Nanjing, Peoples R China 6.Nanjing Univ Chinese Med, Affiliated Hosp, Jiangsu Prov Hosp Chinese Med, Dept Resp Med, Nanjing, Peoples R China 7.Tianjin Med Univ, Natl Clin Res Ctr Canc, Canc Inst & Hosp, Dept Integrat Oncol,Key Lab Canc Prevent & Therapy, Tianjin, Peoples R China 8.Nanchang Univ, Affiliated Hosp 2, Dept Oncol, Nanchang, Peoples R China 9.Chinese Acad Sci Univ, Canc Hosp, Zhejiang Canc Hosp, Dept Med Oncol, 1 Banshan East St, Hangzhou 310022, Peoples R China 10.Cent South Univ, Hunan Canc Hosp, Affiliated Canc Hosp, Xiangya Sch Med,Dept Med Oncol,Lung Canc & Gastroi, Changsha, Peoples R China |
| 推荐引用方式 GB/T 7714 | Wang, Wenxian,Lin, Gen,Guan, Yelan,et al. Treatment outcomes and prognosis of immune checkpoint inhibitors therapy in patients with advanced thymic carcinoma: A multicentre retrospective study[J]. EUROPEAN JOURNAL OF CANCER,2022,174. |
| APA | Wang, Wenxian.,Lin, Gen.,Guan, Yelan.,Zhang, Yuxin.,Xu, Chunwei.,...&Zhang, Yongchang.(2022).Treatment outcomes and prognosis of immune checkpoint inhibitors therapy in patients with advanced thymic carcinoma: A multicentre retrospective study.EUROPEAN JOURNAL OF CANCER,174. |
| MLA | Wang, Wenxian,et al."Treatment outcomes and prognosis of immune checkpoint inhibitors therapy in patients with advanced thymic carcinoma: A multicentre retrospective study".EUROPEAN JOURNAL OF CANCER 174(2022). |
入库方式： OAI收割
来源：合肥物质科学研究院
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。